| Medical and Health Sciences | 2021-2025 | 386 | GB 42 | 99.92 |
| Mathematics and Statistics | 2021-2025 | 453 | GB 21 | 95.79 |
| Epidemiology | Lifetime | 317 | GB 24 | 99.61 |
| Health | Lifetime | 127 | GB 24 | 99.21 |
| Modeling and Simulation | Lifetime | 114 | GB 8 | 97.87 |
| Infectious Diseases | Lifetime | 512 | GB 43 | 98.00 |
| Epidemiology | 2021-2025 | 44 | GB 6 | 99.78 |
| Health | 2021-2025 | 15 | GB 3 | 99.68 |
| Infectious Diseases | 2021-2025 | 180 | GB 17 | 96.92 |
| Modeling and Simulation | 2021-2025 | 69 | GB 4 | 97.65 |
| Econometrics and Quantitative Economics | 2021-2025 | 994 | GB 76 | 93.28 |
| Vaccine Coverage and Hesitancy | Lifetime | 7 | GB 1 | 99.74 |
| COVID-19 epidemiological studies | Lifetime | 25 | GB 8 | 99.62 |
| Cervical Cancer and HPV Research | Lifetime | 76 | GB 8 | 99.50 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 355 | GB 30 | 98.72 |
| Hepatitis B Virus Studies | Lifetime | 334 | GB 21 | 99.04 |
| Influenza Virus Research Studies | Lifetime | 246 | GB 25 | 98.75 |
| Viral gastroenteritis research and epidemiology | Lifetime | 470 | GB 37 | 98.62 |
| Respiratory viral infections research | Lifetime | 399 | GB 38 | 98.45 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 143 | GB 9 | 98.30 |
| Pneumonia and Respiratory Infections | Lifetime | 401 | GB 45 | 98.57 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 816 | GB 135 | 98.19 |
| Genital Health and Disease | Lifetime | 283 | GB 24 | 97.45 |
| Virology and Viral Diseases | Lifetime | 595 | GB 60 | 95.81 |
| Immune responses and vaccinations | Lifetime | 219 | GB 30 | 93.33 |
| Viral Infections and Outbreaks Research | Lifetime | 912 | GB 80 | 93.22 |
| COVID-19 Digital Contact Tracing | Lifetime | 859 | GB 110 | 35.87 |
| COVID-19 epidemiological studies | 2021-2025 | 5 | GB 1 | 99.71 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 5 | GB 1 | 99.80 |
| Influenza Virus Research Studies | 2021-2025 | 23 | GB 2 | 98.80 |
| Pneumonia and Respiratory Infections | 2021-2025 | 41 | GB 7 | 98.65 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 225 | GB 22 | 98.98 |
| Cervical Cancer and HPV Research | 2021-2025 | 39 | GB 4 | 98.65 |
| Respiratory viral infections research | 2021-2025 | 76 | GB 8 | 98.20 |
| Virology and Viral Diseases | 2021-2025 | 19 | GB 2 | 96.25 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 144 | GB 6 | 96.47 |
| Hepatitis B Virus Studies | 2021-2025 | 130 | GB 6 | 97.21 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 378 | GB 55 | 96.43 |
| Viral Infections and Outbreaks Research | 2021-2025 | 116 | GB 16 | 94.05 |
| Immune responses and vaccinations | 2021-2025 | 103 | GB 3 | 88.35 |
| COVID-19 Pandemic Impacts | 2021-2025 | 591 | GB 33 | 86.13 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 231 | GB 7 | 85.77 |
| Global Health Care Issues | 2021-2025 | 882 | GB 104 | 78.34 |
| Neonatal and Maternal Infections | 2021-2025 | 314 | GB 32 | 77.33 |
| Data-Driven Disease Surveillance | 2021-2025 | 428 | GB 39 | 72.75 |
| Genital Health and Disease | 2021-2025 | 915 | GB 74 | 71.06 |
| HIV/AIDS Impact and Responses | 2021-2025 | 455 | GB 41 | 63.07 |